Multi-national study to evaluate the safety and efficacy of a type of AAV5-based gene therapy.

New options to treat Hemophilia B are needed

Genetic disorders result when an error in a gene leads to a problem with the protein it is supposed to create and causes disease.1

Hemophilia B is a rare, genetic bleeding disorder affecting 1 in 20,000 to 34,500 males.2

Gene therapy may correct a gene that is not working properly in order to treat or prevent the disease.3

Gene therapy for hemophilia B treatment focuses on adding a working copy of the gene for factor IX.4

*Etranacogene dezaparvovec (e tra nak’ oh jeen dez ah par’ voe vek) is an investigational product being studied in a phase 3 trial for the treatment of adults with hemophilia B.

Learn More

Learn more about the development of a new therapy for hemophilia B

I am a healthcare provider I am a patient
For more information, please provide the following:

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The company is developing several gene therapies for the treatment of patients with liver/metabolic, central nervous system, and other severe genetic diseases.

This website is maintained by uniQure Inc., having its offices at 113 Hartwell Avenue, Lexington, MA 02421 USA.